NASDAQ:NVUS

Novus Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$7.00
0.00 (0.00 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.53
$7.17
50-Day Range
$9.85
$16.50
52-Week Range
$4.50
$27.32
Volume166,292 shs
Average Volume78,851 shs
Market Capitalization$10.05 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Novus Therapeutics logo

About Novus Therapeutics

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

728th out of 1,350 stocks

Pharmaceutical Preparations Industry

354th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

Is Novus Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Novus Therapeutics stock.
View analyst ratings for Novus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Novus Therapeutics?

Wall Street analysts have given Novus Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics, Inc. (NASDAQ:NVUS) issued its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.64) by $3.87.
View Novus Therapeutics' earnings history
.

When did Novus Therapeutics' stock split? How did Novus Therapeutics' stock split work?

Shares of Novus Therapeutics reverse split on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of Novus Therapeutics stock prior to the reverse split would have 6 shares after the split.

What price target have analysts set for NVUS?

1 equities research analysts have issued 12 month price targets for Novus Therapeutics' shares. Their forecasts range from $43.00 to $43.00. On average, they expect Novus Therapeutics' share price to reach $43.00 in the next year. This suggests a possible upside of 514.3% from the stock's current price.
View analysts' price targets for Novus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the following people:
  • Mr. Jon S. Kuwahara CPA, CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer (Age 55, Pay $295.72k)
  • Mr. Gregory J. Flesher, Consultant (Age 50, Pay $482.13k)
  • Dr. David-Alexandre C. Gros M.D., CEO & Non Independent Director (Age 48)
  • Dr. Steven N. Perrin Ph.D., Pres, Chief Scientific Officer & Non Independent Director (Age 55)

Who are some of Novus Therapeutics' key competitors?

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM) and vTv Therapeutics (VTVT).

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $7.00.

How much money does Novus Therapeutics make?

Novus Therapeutics has a market capitalization of $10.05 million. The biopharmaceutical company earns $-16,010,000.00 in net income (profit) each year or ($21.58) on an earnings per share basis.

How many employees does Novus Therapeutics have?

Novus Therapeutics employs 7 workers across the globe.

What is Novus Therapeutics' official website?

The official website for Novus Therapeutics is novustherapeutics.com.

Where are Novus Therapeutics' headquarters?

Novus Therapeutics is headquartered at 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected].


This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.